(完整版)肺癌基因突变分子靶向治疗.doc

NCCN 2018 第 2 期第 NSCL-H 页载文如下： NCCN Guidelines Version 2.2018 Non-Small Cell Lung Cancer NSCL-H EMERGING TARGETED AGENTS FOR PATIENTS WITH GENETIC ALTERATIONS Genetic Alteration (ie, Driver event) High-level MET amplification or MET exon 14 skipping mutation RET rearrangements HER2 mutations 译为中文即： 基因改变患者的靶向性药物  Available Targeted Agents with Activity Against Driver Event in Lung Cancer Crizotinib 1-5 Cabozantinib 6,7 Vandetanib 8 Ado-trastuzumab emtansine 9 基因改变（即驱动事 肺癌驱动事件可用活性靶向剂 件） 高水平 MET 扩增或 MET 外显子 14 跳跃突 克唑替尼 Crizotinib 1-5 变 卡博替尼 Cabozantinib 6,7 RET 重排 凡德他尼 Vandetanib 8 阿曲曲单抗 HER2 突变 Ado-trastuzumab emtansine 9 【角注原文】 1Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (P, a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-946. 2Camidge RD, Ou S-HI, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer. J Clin Oncol 2014;32(Suppl 5): Abstract 8001. 3Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015;5:850-859. 4Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015;5:842-849. 5Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and cMET overexpresion.J Clin Oncol 2016;34:721-730. 6Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013; 3:630-635. 7Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung canc